☰

Anton Neschadim, Ph.D. - Publications

Affiliations: 
2011 Medical Biophysics University of Toronto, Toronto, ON, Canada 
Area:
Molecular Biology, Immunology
Tree Info Similar researchers PubMed Report error

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Neschadim A, Medin JA. Engineered Thymidine-Active Deoxycytidine Kinase for Bystander Killing of Malignant Cells. Methods in Molecular Biology (Clifton, N.J.). 1895: 149-163. PMID 30539536 DOI: 10.1007/978-1-4939-8922-5_12  0.682
2016 Resetca D, Neschadim A, Medin JA. Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 27488725 DOI: 10.1097/Cji.0000000000000134  0.645
2016 Neschadim A, Kotra LP, Branch DR. Small molecule phagocytosis inhibitors for immune cytopenias. Autoimmunity Reviews. PMID 27296447 DOI: 10.1016/J.Autrev.2016.06.004  0.355
2015 Sato T, Neschadim A, Nakagawa R, Yanagisawa T, Medin JA. Evaluation of Bystander Cell Killing Effects in Suicide Gene Therapy of Cancer: Engineered Thymidylate Kinase (TMPK)/AZT Enzyme-Prodrug Axis. Methods in Molecular Biology (Clifton, N.J.). 1317: 55-67. PMID 26072401 DOI: 10.1007/978-1-4939-2727-2_4  0.69
2015 Neschadim A, Summerlee AJ, Silvertown JD. Targeting the relaxin hormonal pathway in prostate cancer. International Journal of Cancer. 137: 2287-95. PMID 25043063 DOI: 10.1002/Ijc.29079  0.322
2014 Leontyev D, Neschadim A, Branch DR. Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain. Transfusion. 54: 2871-9. PMID 24826802 DOI: 10.1111/Trf.12680  0.303
2014 Neschadim A, Pritzker LB, Pritzker KP, Branch DR, Summerlee AJ, Trachtenberg J, Silvertown JD. Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts. Endocrine-Related Cancer. 21: 459-71. PMID 24812057 DOI: 10.1530/Erc-14-0088  0.311
2014 Purohit MK, Chakka SK, Scovell I, Neschadim A, Bello AM, Salum N, Katsman Y, Bareau MC, Branch DR, Kotra LP. Structure-activity relationships of pyrazole derivatives as potential therapeutics for immune thrombocytopenias. Bioorganic & Medicinal Chemistry. 22: 2739-52. PMID 24685704 DOI: 10.1016/J.Bmc.2014.03.016  0.348
2013 Sato T, Neschadim A, Lavie A, Yanagisawa T, Medin JA. The engineered thymidylate kinase (TMPK)/AZT enzyme-prodrug axis offers efficient bystander cell killing for suicide gene therapy of cancer. Plos One. 8: e78711. PMID 24194950 DOI: 10.1371/Journal.Pone.0078711  0.692
2013 Purohit MK, Scovell I, Neschadim A, Katsman Y, Branch DR, Kotra LP. Disulfide linked pyrazole derivatives inhibit phagocytosis of opsonized blood cells. Bioorganic & Medicinal Chemistry Letters. 23: 2324-7. PMID 23489619 DOI: 10.1016/J.Bmcl.2013.02.064  0.356
2013 Scaife M, Pacienza N, Au BC, Wang JC, Devine S, Scheid E, Lee CJ, Lopez-Perez O, Neschadim A, Fowler DH, Foley R, Medin JA. Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes. Gene Therapy. 20: 24-34. PMID 22241175 DOI: 10.1038/Gt.2011.210  0.685
2012 Neschadim A, Wang JC, Lavie A, Medin JA. Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer. Cancer Gene Therapy. 19: 320-7. PMID 22388453 DOI: 10.1038/Cgt.2012.4  0.665
2012 Neschadim A, Wang JC, Sato T, Fowler DH, Lavie A, Medin JA. Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1002-13. PMID 22273576 DOI: 10.1038/Mt.2011.298  0.699
2011 Walia JS, Neschadim A, Lopez-Perez O, Alayoubi A, Fan X, Carpentier S, Madden M, Lee CJ, Cheung F, Jaffray DA, Levade T, McCart JA, Medin JA. Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates. Human Gene Therapy. 22: 679-87. PMID 21280983 DOI: 10.1089/Hum.2010.195  0.635
2010 Likar Y, Zurita J, Dobrenkov K, Shenker L, Cai S, Neschadim A, Medin JA, Sadelain M, Hricak H, Ponomarev V. A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1395-403. PMID 20810757 DOI: 10.2967/Jnumed.109.074344  0.597
2010 Silvertown JD, Neschadim A, Liu HN, Shannon P, Walia JS, Kao JC, Robertson J, Summerlee AJ, Medin JA. Relaxin-3 and receptors in the human and rhesus brain and reproductive tissues. Regulatory Peptides. 159: 44-53. PMID 19778557 DOI: 10.1016/J.Regpep.2009.09.007  0.545
2009 Scaife MD, Neschadim A, Fowler DH, Medin JA. Novel application of lentiviral vectors towards treatment of graft-versus-host disease. Expert Opinion On Biological Therapy. 9: 749-61. PMID 19456209 DOI: 10.1517/14712590903002021  0.624
2009 Medin J, Walia J, Neschadim A, Fan X, Madden M, Cheung F, Jaffray D, Levade T, Brady R, McCart JA. 87. Outcomes of testing Lentivector-mediated Gene Therapy for Farber Disease in Non-Human Primates Molecular Genetics and Metabolism. 96: S31. DOI: 10.1016/J.Ymgme.2008.11.088  0.568
2007 Neschadim A, McCart JA, Keating A, Medin JA. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 1407-16. PMID 18022569 DOI: 10.1016/J.Bbmt.2007.09.014  0.649
2007 Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 962-70. PMID 17375075 DOI: 10.1038/Mt.Sj.6300122  0.702
2007 Silvertown JD, Symes JC, Neschadim A, Nonaka T, Kao JC, Summerlee AJ, Medin JA. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 21: 754-65. PMID 17197386 DOI: 10.1096/Fj.06-6847Com  0.555
2006 Neschadim A, Sato T, Fowler DH, Lavie A, Medin JA. Development of Improved Lentiviral ‘Suicide’ Gene Therapy for the Management of GvHD and GvL/GvT Responses in Allogeneic BMT. Blood. 108: 3256-3256. DOI: 10.1182/Blood.V108.11.3256.3256  0.677
2005 Sato T, Neschadim A, Rasaiah VI, Konrad M, Fowler DH, Lavie A, Medin JA. A Novel Suicide Gene Therapy Approach for Reduction of GvHD Using Lentiviral Delivery of a Modified Human Thymidylate Monophosphate Kinase. Blood. 106: 5252-5252. DOI: 10.1182/Blood.V106.11.5252.5252  0.701
2005 Sato T, Neschadim A, Rasaiah VI, Konrad M, Fowler DH, Lavie A, Medin JA. Improved Suicide Gene Therapy: Lentiviral Gene Transfer of Equine Herpes Virus Type 4 Thymidine Kinase into Target Cells. Blood. 106: 5251-5251. DOI: 10.1182/Blood.V106.11.5251.5251  0.701
Show low-probability matches.